SoRI-9409 explained

SoRI-9409 is a mixed mu opioid receptor partial agonist and delta opioid receptor antagonist, used in biomedical research. It produces moderate analgesic effects without development of tolerance and with reduced withdrawal symptoms compared to standard opioid analgesics,[1] as well as showing anti-addictive effects that may be useful in the treatment of alcoholism.[2] [3]

Notes and References

  1. Wells JL, Bartlett JL, Ananthan S, Bilsky EJ . In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence . The Journal of Pharmacology and Experimental Therapeutics . 297 . 2 . 597–605 . May 2001 . 11303048 .
  2. Nielsen CK, Simms JA, Pierson HB, Li R, Saini SK, Ananthan S, Bartlett SE . A novel delta opioid receptor antagonist, SoRI-9409, produces a selective and long-lasting decrease in ethanol consumption in heavy-drinking rats . Biological Psychiatry . 64 . 11 . 974–81 . December 2008 . 18774553 . 3888668 . 10.1016/j.biopsych.2008.07.018 .
  3. Nielsen CK, Simms JA, Bito-Onon JJ, Li R, Ananthan S, Bartlett SE . The delta opioid receptor antagonist, SoRI-9409, decreases yohimbine stress-induced reinstatement of ethanol-seeking . Addiction Biology . 17 . 2 . 224–34 . March 2012 . 21309957 . 3906128 . 10.1111/j.1369-1600.2010.00295.x .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "SoRI-9409".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.